Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in chol...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2020-04, Vol.382 (16), p.1520-1530 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1530 |
|---|---|
| container_issue | 16 |
| container_start_page | 1520 |
| container_title | The New England journal of medicine |
| container_volume | 382 |
| creator | Raal, Frederick J Kallend, David Ray, Kausik K Turner, Traci Koenig, Wolfgang Wright, R. Scott Wijngaard, Peter L.J Curcio, Danielle Jaros, Mark J Leiter, Lawrence A Kastelein, John J.P |
| description | This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540. |
| doi_str_mv | 10.1056/NEJMoa1913805 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2381628775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2381628775</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-47f487d11fec911a1b56c05773008b438b1c25e64f19ee17978286fe0f261fc53</originalsourceid><addsrcrecordid>eNp10EtLxDAUBeAgijM-lm6lIIKbam7TNslSBnUUHxtdlzTeOB2aZkzaxfjrTRkVFMzmLvJxOBxCjoCeAy3Ki8eruwenQAITtNgiUygYS_OclttkSmkm0pxLNiF7ISxpfJDLXTJhGUiecT4ld7edbpvQeNUlxvmkX2Dy7FH1Frs-cSaZY4_efazf3BCSa2WbtlFtMl-v0OuFazGM3y3aRh2QHaPagIdfd5-8XF89z-bp_dPN7ezyPtUFpX3sY3LBXwEMagmgoC5KTQvOGaWizpmoQWcFlrkBiQhccpGJ0iA1WQlGF2yfnG1yV969D7FAZZugsW1Vh7FklTEBZSY4H-nJH7p0g-9iu6gkBRnHGlW6Udq7EDyaauUbq_y6AlqNI1e_Ro7--Ct1qC2-_ujvVSM43QBrQ9Xh0v4T9Am6Z4Gw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2390195335</pqid></control><display><type>article</type><title>Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Raal, Frederick J ; Kallend, David ; Ray, Kausik K ; Turner, Traci ; Koenig, Wolfgang ; Wright, R. Scott ; Wijngaard, Peter L.J ; Curcio, Danielle ; Jaros, Mark J ; Leiter, Lawrence A ; Kastelein, John J.P</creator><creatorcontrib>Raal, Frederick J ; Kallend, David ; Ray, Kausik K ; Turner, Traci ; Koenig, Wolfgang ; Wright, R. Scott ; Wijngaard, Peter L.J ; Curcio, Danielle ; Jaros, Mark J ; Leiter, Lawrence A ; Kastelein, John J.P ; ORION-9 Investigators</creatorcontrib><description>This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1913805</identifier><identifier>PMID: 32197277</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Apolipoproteins ; Arteriosclerosis ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Confidence intervals ; Deoxyribonucleic acid ; DNA ; Dosage ; Genotypes ; Health risk assessment ; Hypercholesterolemia ; Immunoglobulins ; Kexin ; Low density lipoprotein ; Monoclonal antibodies ; Proprotein convertases ; siRNA ; Software ; Statins ; Subtilisin</subject><ispartof>The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530</ispartof><rights>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2020 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-47f487d11fec911a1b56c05773008b438b1c25e64f19ee17978286fe0f261fc53</citedby><cites>FETCH-LOGICAL-c500t-47f487d11fec911a1b56c05773008b438b1c25e64f19ee17978286fe0f261fc53</cites><orcidid>0000-0003-0508-0954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1913805$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1913805$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32197277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raal, Frederick J</creatorcontrib><creatorcontrib>Kallend, David</creatorcontrib><creatorcontrib>Ray, Kausik K</creatorcontrib><creatorcontrib>Turner, Traci</creatorcontrib><creatorcontrib>Koenig, Wolfgang</creatorcontrib><creatorcontrib>Wright, R. Scott</creatorcontrib><creatorcontrib>Wijngaard, Peter L.J</creatorcontrib><creatorcontrib>Curcio, Danielle</creatorcontrib><creatorcontrib>Jaros, Mark J</creatorcontrib><creatorcontrib>Leiter, Lawrence A</creatorcontrib><creatorcontrib>Kastelein, John J.P</creatorcontrib><creatorcontrib>ORION-9 Investigators</creatorcontrib><title>Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540.</description><subject>Apolipoproteins</subject><subject>Arteriosclerosis</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Confidence intervals</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Dosage</subject><subject>Genotypes</subject><subject>Health risk assessment</subject><subject>Hypercholesterolemia</subject><subject>Immunoglobulins</subject><subject>Kexin</subject><subject>Low density lipoprotein</subject><subject>Monoclonal antibodies</subject><subject>Proprotein convertases</subject><subject>siRNA</subject><subject>Software</subject><subject>Statins</subject><subject>Subtilisin</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10EtLxDAUBeAgijM-lm6lIIKbam7TNslSBnUUHxtdlzTeOB2aZkzaxfjrTRkVFMzmLvJxOBxCjoCeAy3Ki8eruwenQAITtNgiUygYS_OclttkSmkm0pxLNiF7ISxpfJDLXTJhGUiecT4ld7edbpvQeNUlxvmkX2Dy7FH1Frs-cSaZY4_efazf3BCSa2WbtlFtMl-v0OuFazGM3y3aRh2QHaPagIdfd5-8XF89z-bp_dPN7ezyPtUFpX3sY3LBXwEMagmgoC5KTQvOGaWizpmoQWcFlrkBiQhccpGJ0iA1WQlGF2yfnG1yV969D7FAZZugsW1Vh7FklTEBZSY4H-nJH7p0g-9iu6gkBRnHGlW6Udq7EDyaauUbq_y6AlqNI1e_Ro7--Ct1qC2-_ujvVSM43QBrQ9Xh0v4T9Am6Z4Gw</recordid><startdate>20200416</startdate><enddate>20200416</enddate><creator>Raal, Frederick J</creator><creator>Kallend, David</creator><creator>Ray, Kausik K</creator><creator>Turner, Traci</creator><creator>Koenig, Wolfgang</creator><creator>Wright, R. Scott</creator><creator>Wijngaard, Peter L.J</creator><creator>Curcio, Danielle</creator><creator>Jaros, Mark J</creator><creator>Leiter, Lawrence A</creator><creator>Kastelein, John J.P</creator><general>Massachusetts Medical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0508-0954</orcidid></search><sort><creationdate>20200416</creationdate><title>Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia</title><author>Raal, Frederick J ; Kallend, David ; Ray, Kausik K ; Turner, Traci ; Koenig, Wolfgang ; Wright, R. Scott ; Wijngaard, Peter L.J ; Curcio, Danielle ; Jaros, Mark J ; Leiter, Lawrence A ; Kastelein, John J.P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-47f487d11fec911a1b56c05773008b438b1c25e64f19ee17978286fe0f261fc53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apolipoproteins</topic><topic>Arteriosclerosis</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Confidence intervals</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Dosage</topic><topic>Genotypes</topic><topic>Health risk assessment</topic><topic>Hypercholesterolemia</topic><topic>Immunoglobulins</topic><topic>Kexin</topic><topic>Low density lipoprotein</topic><topic>Monoclonal antibodies</topic><topic>Proprotein convertases</topic><topic>siRNA</topic><topic>Software</topic><topic>Statins</topic><topic>Subtilisin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raal, Frederick J</creatorcontrib><creatorcontrib>Kallend, David</creatorcontrib><creatorcontrib>Ray, Kausik K</creatorcontrib><creatorcontrib>Turner, Traci</creatorcontrib><creatorcontrib>Koenig, Wolfgang</creatorcontrib><creatorcontrib>Wright, R. Scott</creatorcontrib><creatorcontrib>Wijngaard, Peter L.J</creatorcontrib><creatorcontrib>Curcio, Danielle</creatorcontrib><creatorcontrib>Jaros, Mark J</creatorcontrib><creatorcontrib>Leiter, Lawrence A</creatorcontrib><creatorcontrib>Kastelein, John J.P</creatorcontrib><creatorcontrib>ORION-9 Investigators</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raal, Frederick J</au><au>Kallend, David</au><au>Ray, Kausik K</au><au>Turner, Traci</au><au>Koenig, Wolfgang</au><au>Wright, R. Scott</au><au>Wijngaard, Peter L.J</au><au>Curcio, Danielle</au><au>Jaros, Mark J</au><au>Leiter, Lawrence A</au><au>Kastelein, John J.P</au><aucorp>ORION-9 Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2020-04-16</date><risdate>2020</risdate><volume>382</volume><issue>16</issue><spage>1520</spage><epage>1530</epage><pages>1520-1530</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>32197277</pmid><doi>10.1056/NEJMoa1913805</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0508-0954</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2381628775 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Apolipoproteins Arteriosclerosis Cardiovascular disease Cardiovascular diseases Cholesterol Confidence intervals Deoxyribonucleic acid DNA Dosage Genotypes Health risk assessment Hypercholesterolemia Immunoglobulins Kexin Low density lipoprotein Monoclonal antibodies Proprotein convertases siRNA Software Statins Subtilisin |
| title | Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T20%3A05%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inclisiran%20for%20the%20Treatment%20of%20Heterozygous%20Familial%20Hypercholesterolemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Raal,%20Frederick%20J&rft.aucorp=ORION-9%20Investigators&rft.date=2020-04-16&rft.volume=382&rft.issue=16&rft.spage=1520&rft.epage=1530&rft.pages=1520-1530&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1913805&rft_dat=%3Cproquest_cross%3E2381628775%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2390195335&rft_id=info:pmid/32197277&rfr_iscdi=true |